CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bayer Schering Pharma AG (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bayer Schering Pharma AG (ADR)
Muellerstrasse 178
Phone: (30) 468-1111p:30 468-1111 Berlin, 13353  Germany Ticker: SHRGYSHRGY

This company ceased filing statements with the SEC on 6/4/2007.
This company is no longer actively traded on any major stock exchange.

Business Summary
Bayer Schering Pharma AG, formerly Schering AG, is a global research-based company engaged in the development, manufacture and marketing of pharmaceutical products. It is engaged in research on new drugs and therapies. It divides its activities into four main segments. Women’s Healthcare includes such areas as female contraception, menopause management and gynecological therapies. Diagnostic Imaging includes magnetic resonance imaging (MRI) and X-ray contrast media. Specialty Medicine includes hemophilia therapies, drugs for solid-tumor therapy and for treating diseases of the central nervous system. General Medicine includes treatment in the areas of cardiovascular and metabolic diseases, thromboembolic diseases and pulmonary hypertension. The Company's products include Yasmin, Yasminelle, Betaferon, Betaseron, Kogenate, Adalat, Avalox, Cipro, Mirena, Levitra, among others. The Company’s production locations are in Europe, the United States, Latin America and Asia.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/200612/31/2005YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Supervisory Board RichardPott 57 8/26/2009 8/26/2009
Chairman of the Board of Management AndreasFibig 48 9/1/2008 9/1/2008
Vice Chairman of the Supervisory Board Heinz G.Webers 50 1/1/2009 4/27/1999
10 additional Officers and Directors records available in full report.

General Information
Number of Employees: 23,050 (As of 9/30/2006)
Outstanding Shares: 190,882,000 (As of 12/31/2006)
Shareholders: 188
Stock Exchange: OTC
Fax Number: (30) 468-15305
Email Address: investor.relations@schering.de


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023